[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-328505-105":59,"doc-detail-328505-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","personalized-assessment-for-cancer-prevention-detection-and-treatment-editorial","Personalized Assessment for Cancer Prevention, Detection, and Treatment - Editorial","","Editorial overview emphasizing precision oncology as a response to cancer heterogeneity, where genetic, environmental, and lifestyle differences drive variable treatment outcomes. Describes how next-generation sequencing and molecular targeting enable mutation identification, mutational-burden quantification, and development of drugs inhibiting tumor-specific alterations. Highlights research examples linking aggressive cancer-associated fibroblasts with chemo-resistance, and evaluates measurable biomarkers such as Ki-67 and emerging biomarker panels in early-stage endometrial and gastric cancer, including implications for survival and prognosis.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/personalized-assessment-for-cancer-prevention-detection-and-treatment-editorial/328505/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/personalized-assessment-for-cancer-prevention-detection-and-treatment-editorial/328505.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the core idea behind personalized (precision) assessment in cancer care?","Question",{"text":113,"@type":114},"Cancers are not identical, and patients may respond differently due to genetic, environmental, and lifestyle factors, enabling more tailored prevention and treatment decisions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do NGS technologies support personalized oncology?",{"text":118,"@type":114},"They improve analysis of tumor DNA and help identify driver mutations, estimate mutational burden, and guide the development of molecularly targeted drugs.",{"name":120,"@type":111,"acceptedAnswer":121},"Which biomarkers are discussed as measurable tools for clinical use?",{"text":122,"@type":114},"Ki-67 is highlighted for prognostic value, and the text also discusses a broader search for novel biomarkers in cancers such as endometrial and gastric cancer, including chemokines and related signaling components.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},328505,1790216834,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":39,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Editorial  \nPersonalized Assessment for Cancer Prevention, Detection, and Treatment  \nLaura Paleari   \nCitation: Paleari, L. Personalized Assessment for Cancer Prevention, Detection, and Treatment. Int. J. Mol. Sci. 2024, 25, 8140. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25158140](10.3390/ijms25158140)  \nReceived: 14 July 2024  \nAccepted: 23 July 2024  \nPublished: 26 July 2024  \nCopyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nResearch, Innovation and HTA Unit, Liguria Health Authority, A.Li.Sa., 16121 Genova, Italy; [laura.paleari@alisa.liguria.it](laura.paleari@alisa.liguria.it)  \nThe intention of this Special Issue is to highlight research that aims to recognize cancer’s complexity to better prevent or treat its occurrence.  \nPersonalized (or precision) medicine in oncology is grounded in the idea that cancers are not all the same and people may respond differently to treatments due to their genetic, environmental, and lifestyle characteristics [1] . Before the advent of precision medicine, cancer treatments were mainly based on standardized approaches, such as chemotherapy and radiotherapy, with significant side effects and variable results. Precision medicine has essentially changed this landscape, enabling more personalized, effective, and targeted care [1] . The improvement in the technologies used for the analysis of cancer cell DNA (the so-called NGS, next generation sequencing technologies) has led to a change in the cancer treatment paradigm, thanks to continuous studies. They are designed to address the following: identify specific genetic mutations that drive tumor growth; quantify the mutational burden, which can lead to the discovery of resistance to treatment mechanisms; and develop molecularly targeted drugs designed to inhibit specific alterations in neoplastic cells [2] . An example of personalized research is represented by Suliman and colleagues’work, which aimed to correlate chemo-resistance with biological variables in endometrial cancer (EC) patients [3] . To reach this goal, they explored the functional association between aggressive cancer-associated fibroblast cells (CAFs), derived from EC patients, and resistance to chemo/targeted drugs [3] . Their results showed a positive correlation between grade 3 (p = 0.025) and stage 3/4 diseases (p = 0.0106) with aggressive CAFs and the post-surgery event (PSE) . Furthermore, aggressive CAFs, derived from patients with PSE, displayed resistance to paclitaxel and lenvatinib [3] .  \nFurthermore, the clinical utilization of measurable biomarkers has been possible by personalized medicine. This approach aims to avoid ineffective treatments by the evaluation of specific genetic characteristics of each patient. In the clinical setting, the Ki-67 proliferation marker is well known; it often correlates with an unfavorable prognosis in tumors [4,5], even if its use is to date has mainly been restricted to breast cancers (BCs) [6–9] . Recently, a retrospective study on a cohort of women affected by EC has been published, with the intention of exploring Ki-67’s predictive and prognostic role [9] . The results of this research suggest a positive role for the Ki-67 index as a prognostic and predictive marker of response to hormone treatments in early-stage ECs with a statistically significant benefit in terms of disease-free survival (DFS) [HR = 0.25 (95% CI; 0.09–0.69), p = 0.008] and overall survival (OS) [HR = 0.30 (95% CI; 0.10–0.87), p = 0.03] in the high-expressing Ki-67 group treated with hormone therapy [10] . Moreover, a comprehensive analysis to detect novel biomarkers has been published, with a focus on the diagnosis and progre","cbCaigtUFgfUjhDq","https://ap.wps.com/l/cbCaigtUFgfUjhDq","pdf",152166,"English","# Personalized Assessment for Cancer Prevention, Detection, and Treatment\n## Precision oncology and molecular targeting\n## Biomarkers and clinical predictive value\n## Predictive medicine and patient quality of life","[{\"question\":\"What is the core idea behind personalized (precision) assessment in cancer care?\",\"answer\":\"Cancers are not identical, and patients may respond differently due to genetic, environmental, and lifestyle factors, enabling more tailored prevention and treatment decisions.\"},{\"question\":\"How do NGS technologies support personalized oncology?\",\"answer\":\"They improve analysis of tumor DNA and help identify driver mutations, estimate mutational burden, and guide the development of molecularly targeted drugs.\"},{\"question\":\"Which biomarkers are discussed as measurable tools for clinical use?\",\"answer\":\"Ki-67 is highlighted for prognostic value, and the text also discusses a broader search for novel biomarkers in cancers such as endometrial and gastric cancer, including chemokines and related signaling components.\"}]","Personalized Assessment for Cancer Prevention, Detection, and Treatment - Editorial | PDF",1789979997]